Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 5Leukemia, Myelomonocytic, Chronic 3Targeted Therapy 1Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancies 1Glioma 1Cholangiocarcinoma 1

Interventions

fludarabine 19Whole-Body Irradiation 18Cyclophosphamide 17fludarabine phosphate 16ruxolitinib 15Mycophenolic Acid 14Specimen Handling 13Tacrolimus 11Azacitidine 11Biopsy 10Peripheral Blood Stem Cell Transplantation 9Melphalan 9Cytarabine 9venetoclax 8Sirolimus 8Busulfan 8Stem Cell Transplantation 6Injections 6Granulocyte Colony-Stimulating Factor 6Daunorubicin 5Cyclosporine 5CPX-351 5luspatercept 4ivosidenib 4itacitinib 4fedratinib 4decitabine and cedazuridine drug combination 4Thiotepa 4Liposomes 4Cyclosporins 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × olutasidenib × 1 year × Clear all
NCT05564390 2026-06-03

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡